{"entity":{"id":"nct04501120","kind":"trial","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","aka":[],"tldr":"A phase 1/2 trial of Azacitidine, Olverembatinib in acute myeloid leukaemia, run by Ascentage Pharma Group Inc., now recruiting.","summary":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML is a phase 1/2 interventional study registered as NCT04501120 by Ascentage Pharma Group Inc., with 682 participants planned, started 2020-09-28 and due to reach its primary completion in 2028-09. Interventions recorded: Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT, Azacitidine, Lisaftoclax (APG-2575). Conditions listed: Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04501120","url":"https://clinicaltrials.gov/study/NCT04501120"}],"tags":["ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["azacitidine","olverembatinib"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04501120","phase":"1/2","setting":"A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML","sponsor":"Ascentage Pharma Group Inc.","enrolled":682,"outcomes":[]},"route":"/trials/nct04501120/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}